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 ABSTRACT
Background: Economic evaluations help health authorities facing budget constraints. This study compares 
the health-related quality of life (HRQOL) and costs in patient subgroups on haemodialysis (HD) and renal 
transplantation (KT). Methods: In a prospective study with follow-up of 1-3 years, we performed a cost-
utility analysis of KT vs. HD, adopting a lifetime horizon. A societal perspective was taken. Costs for organ 
procurement, KT eligibility, transplant surgery and follow-up of living donors were included. Key clinical 
events were recorded. HRQOL was assessed using the EuroQol instrument. Results: The HRQOL remained 
stable on HD patients. After KT, mean utility score improved at 3 months while mean EQ-VAS scores showed 
a sustained improvement. Mean annual cost for HD was 32,567.57€. Mean annual costs for KT in the year-1 
and in subsequent years were, 60,210.09€ and 12,956.77€ respectively. Cost for initial hospitalization aver-
aged 18,740.74€. HLA-mismatches increased costs by 75% for initial hospitalization (p < 0.001) and 41% in 
the year-1 (p < 0.05), and duplicate the risk of readmission in the year-1 (p < 0.05). The incremental cost-
utility ratio was 5,534.46€/QALY, increasing 35% when costs for organ procurement were added. KT costs 
were 41,541.63€ more but provided additional 7.51 QALY. Conclusions: The KT is cost-effective compared 
with HD. Public funding should reflect the value created by the intervention and adapt to the organ demand.
Key words: Economic evaluation; haemodialysis; public funding; QALY; quality-adjusted life years; renal 
transplantation.
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 INTRODUCTION
End-stage renal disease (ESRD) is a global public 
health problem. The societal impact of chronic kidney 
disease puts pressure on healthcare systems1. Por-
tugal, with a population of 10 million inhabitants, is 
one of the European countries with the highest preva-
lence of ESRD (1,000-1,160 per million inhabitants)2. 
An increase in ESRD is expected due to the ageing 
of the population, with the current proportion of 16% 
of the population aged over 65 projected to double 
in 20503, a prevalence of diabetic nephropathy of 
7%, with 30% of these patients suffering from newly 
diagnosed ESRD4, and a high prevalence of hyper-
tension (42%)5. Renal transplantation (KT) improves 
patient survival and health-related quality of life 
(HRQOL) and has a favourable cost-effectiveness 
ratio6. However, transplant eligibility and the avail-
ability of organs for transplantation constrain this 
treatment option. The impact of the newer immuno-
suppressive (IS) agents on cost-effectiveness and 
HRQOL is still unclear7. Few studies have used pref-
erence instruments to assess HRQOL in ESRD 
patients8. The absence of information about adverse 
events and hospitalizations is another major 
limitation of existing economic evaluations9. Trans-
portation costs and lost productivity have rarely been 
included in the analysis10,11.
During 2012, 17,533 patients in Portugal received 
renal replacement therapy. About 60% were on pub-
licly funded haemodialysis (HD) in private for-profit 
dialysis centres, 36% had a kidney transplant and 
4% were on peritoneal dialysis12. This study aimed 
to evaluate HRQOL and costs of KT compared to HD 
in private dialysis-centres.
 SUBJECTS AND METHODS
This prospective observational study was con-
ducted in a single-centre for KT in Portugal, from 
2008 to 2010. The study population included patients 
aged ≥ 18 years, on chronic HD for at least three 
months, who were wait-listed for KT, and who had 
agreed to respond to the EuroQol-5D (EQ-5D) instru-
ment, a generic preference-based questionnaire. The 
EQ-5D includes a classification system (EQ-5Dprofile) 
and a visual analogue scale (EQ-VAS). The EQ-5Dprofile
 RESUMO
Introdução: As análises económicas aplicadas à saúde são fontes úteis de informação à alocação de 
recursos escassos. Este estudo compara a qualidade de vida e os custos em subgrupos de doentes em 
hemodiálise e transplantados renais. Métodos: No âmbito dum estudo prospectivo com follow-up de 1-3 
anos, realizou-se uma análise custo-utilidade do transplante renal vs hemodiálise, na perspectiva da socie-
dade. O horizonte temporal escolhido foi o ciclo de vida dos doentes. Incluíram-se os custos da colheita 
de órgãos, seleção dos candidatos a transplante, cirurgia do transplante e follow-up dos dadores vivos. 
Registaram-se os eventos clínicos. Utilizou-se o EuroQol-5D na avaliação da qualidade de vida. Resultados:
Não se observou variação da QVRS nos doentes em hemodiálise. Observou-se melhoria do índice de utili-
dade ao 3º mês de transplante e os valores na escala EQ-VAS melhoraram em todos os tempos de obser-
vação. O custo médio por doente em hemodiálise foi 32.567,57€. O custo médio no 1º ano de transplante 
foi de 60.210,09€ e nos anos seguintes 12.956,77€. O custo médio do internamento inicial foi de 18.740.74€. 
Cada incompatibilidade-HLA aumentou em 75% o custo do internamento inicial (p < 0.001) e em 41% o 
custo no 1º ano (p < 0.05), e duplicou o risco de internamento no 1º ano (p < 0.05). O rácio custo-utilidade 
incremental foi 5.534,46€/QALY; a inclusão dos custos da colheita de órgãos para transplante agravou esse 
rácio em 35%. O transplante gera um acréscimo de 41.541,63€ e um ganho adicional de 7,51 QALY. Con-
clusões: O transplante renal é custo-efetivo comparado com a hemodiálise; consequentemente, o financia-
mento deve refletir o valor criado pela intervenção e adequar-se à sua procura.
Palavras-Chave: Análise económica; anos de vida ajustados pela qualidade; financiamento público; 
hemodiálise; QALY; transplante renal.
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includes five dimensions: mobility, self-care, usual 
activities, pain/discomfort and anxiety/depression. 
Responses record three levels of severity: no prob-
lems, some problems, and extreme problems, result-
ing in 243 possible sets of values. These unique 
health states are converted to a single summary 
index by applying scores from a standard set of 
preference weights, which were not available for the 
Portuguese population. As an alternative, utility val-
ues elicited from respondents in the United Kingdom 
were applied. The EQ-VAS records the respondents 
rating of his/her overall health status on a graduated, 
vertical visual analogue scale ranging from 0 to 100.
The HRQOL was assessed in HD patients (baseline) 
and two years after in those remaining on the trans-
plant list. Follow-up interviews were scheduled at 3, 
6, 12, 24 and 36 months after KT, including patients 
who had lost their graft. The questionnaire was 
self-administered.
At enrolment, demographic and socio-economic 
data were collected on: gender, age, marital status, 
household income, employment and education. Each 
transplant recipient acted as his/her own control on 
HD. Medical records were searched for the following 
information: primary cause of ESRD, time on HD, 
co-morbidities, clinical outcomes, medication (includ-
ing IS regimens), sensitization to HLA-antigens (PRA), 
number of mismatches, extended criteria donor (ECD) 
kidneys, graft source (living/deceased), high immu-
nological risk (< 2 donor-recipient compatibilities and 
PRA ≥ 25%). The ECD was defined as a deceased 
donor with a least one criterion: aged > 55 years, 
stroke as cause of death, history of hypertension or 
diabetes mellitus (DM) for at least 10 years, or cold 
ischemic time >24 hours)13. New-onset of diabetes 
Mellitus (NODAT)14, incidence of arterial hypertension, 
dyslipidemia, depression and neoplastic disease were 
included as adverse effects of IS.
The impact of KT on HRQOL was evaluated by 
comparing EQ-5D change scores from 2-years after 
KT to baseline. We investigated the associations 
between HRQOL and costs with patient characteristics 
and clinical events.
As a societal viewpoint was taken, both direct 
and indirect costs were included. Direct costs refer 
to all the resources consumed in delivering care to 
the patient, and were categorized into medical and 
non-medical costs. Indirect costs include lost pro-
ductivity associated with early retirement and mor-
bidity. Costs were reported up to 2011, expressed in 
Euro (€) and assigned to HD and KT as follows.
 Haemodialysis programme
Haemodialysis was considered the current clinical 
practice. Resource consumption was reported to the 
year prior to KT and assumed to be constant, annu-
ally. National Health Service (NHS) payments to the 
private dialysis centres are based on a composite 
rate, at a price of 470.09€/patient/week. This com-
prehensive price covers all services of HD including 
staff remuneration, medication (antihypertensive, 
anaemia and bone management agents), diagnostic 
procedures related to renal disease and management 
of vascular access.
Costs of hospitalizations were obtained from 
diagnosis-related groups (DRG).
Transportation costs were individualized, based 
on the price per Km paid by NHS, the distance 
between home and the HD centre and the number 
of transportations.
Lost productivity was valued by gross wages 
according to the human capital approach. We mul-
tiplied the sum of the base wage, overtime pay and 
regular benefits by 1.2375, to account for the Social 
Security contributive rate and the result by 14 months 
(including the vacation and Christmas subsidies) to 
obtain the annual salary (18,646.20€). Productivity 
per working day was calculated from annual wages 
divided by 230, representing the effective days of 
work per year (excluding weekends and holidays).
 Transplantation
Costs of organ donation
The costs associated with cadaveric donation were 
assumed to be for the following: a per diem rate at 
the Intensive Care Unit, histocompatibility tests 
obtained from hospital records and organ harvesting 
derived from DRG corresponding to nephrectomy.
The evaluation of a living donor candidate included 
consultations and diagnostic procedures. Hospitalization 
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costs for living donation were derived from DRG data 
for nephrectomies. Living donor follow-up costs were 
based on individualized data.
Transplant recipients
The surgical procedure was valued by the price 
of ambulatory kidney surgery extracted from the 
national DRG database.
We applied mixed costing methods for the initial 
and subsequent hospitalizations. For the Trans-
plant Unit, the main setting of admissions, a micro-
costing approach was applied. We collected indi-
vidualized data for medication and diagnostic 
procedures (the main components of costs). Esti-
mates of the average daily wage of health profes-
sionals were based on national remuneration 
tables, and the remaining daily costs were extract-
ed from hospital records and multiplied by the 
length of hospitalization.
As hospitalizations in departments other than the 
Transplant Unit were uncommon, costs were derived 
from the national DRG database.
As specific drugs for transplanted patients are 
fully paid by the NHS, the doses and cost informa-
tion were extracted from the hospital pharmacy 
database.
Costs of diagnostic procedures, consultations and 
urgency episodes were obtained from the national 
database, including reimbursements paid by NHS to 
hospitals.
Transportation costs and productivity changes 
were described on the HD programme.
 Cost-utility of dialysis vs. renal transplantation
Once costs and benefits had been determined, a 
simple ratio of the mean incremental costs by the 
mean incremental utility scores provided the cost 
utility for HD relative to RT. In our economic model, 
data beyond the observation period was extrapo-
lated. Based on an ERA-EDTA cohort15 the projected 
life expectancy on dialysis and KT was assumed to 
be 6.7 and 16.4 years, respectively. An utility of zero 
was assigned to patients who died. We applied a 
three and five per cent per year discount rate to 
encompass the range typically employed in economic 
evaluations.
 Sensitivity analysis
To explore the impact of uncertainty on our find-
ings, a series of one-way sensitivity analysis were 
undertaken. Four factors were chosen: a 3% and 5% 
discount rate applied only to the costs (presenting 
QALYs in the undiscounted form), exclusion of pro-
ductivity changes, equal life expectancy for HD and 
KT and inclusion of organ procurement costs.
 Statistical Analysis
Descriptive statistics used were the arithmetic 
mean and 95% confidence intervals for normally 
distributed samples, and median with interquartile 
ranges for skewed variables. We used the student’s 
t-test and one-way ANOVA to compare means 
between continuous variables for normally distrib-
uted samples or Mann-Whitney U-tests for skewed 
samples. The Kruskal-Wallis test was used to com-
pare mean differences between skewed variables in 
more than two groups. We used the Friedman test 
to investigate the presence of global changes in 
HRQOL during the study period, and the Wilcoxon 
test was used to identify differences of EQ-5D utility 
and EQ-VAS scores between paired time observa-
tions using the Bonferroni correction. We used mul-
tiple regression models to identify significant predic-
tors of HRQOL and costs. Statistical significance was 
assumed for p values < 0.05. We used the software
Statistical Package for Social Sciences, version 13.0 
for Windows.
 RESULTS
Population
Of 384 wait-listed patients enrolled, sixty-five 
underwent KT. Their characteristics are summarized 
in Table 1. Baseline IS for transplanted patients 
consisted of steroids, tacrolimus and mycopheno-
late mofetil. Induction IS included Basiliximab to 
patients at low immunologic risk (49%) and poly-
clonal antibody for those with high immunologic 
risk (51%).
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HRQOL on HD
At baseline, mean EQ-5D utility was rated at 0.75; 
women reported a lower value (p < 0.001). Mean 
EQ-VAS score was 63.54; diabetics reported a lower 
value (p < 0.05). A second evaluation of HRQOL was 
requested from 165 patients remaining on the trans-
plant list. The response rate was 50%. Gender, age, 
education level and wage did not differ between 
respondents and non-respondents. There was no 
change in HRQOL between the two interviews. Mul-
tiple regression analyses failed to show relationships 
between HRQOL measures and baseline variables.
Changes in EQ-5D utility and EQ-VAS scores after KT
Transplanted patients had a significant change of 
EQ-5D utility (p < 0.01) and EQ-VAS scores (p < 0.001) 
over time; in comparison with HD, median utilities 
improved at 3-months after KT (p < 0.01) with no 
significant change thereafter, and median EQ-VAS 
showed a sustained improvement (p < 0.001).
Median EQ-5D utility was higher on successful 
transplantation compared to renal allograft loss: 0.85 
vs. 0.42 in the first year (p < 0.05), and 0.92 vs. 0.19 
in subsequent years (p < 0.01), respectively.
Compared to the baseline, the evaluation of HRQOL 
2-year after KT showed no significant change in EQ-5D 
utility, although there was a change on EQ-VAS (p < 
0.001). The EQ-VAS change score averaged 13.94 (95% 
CI 8.47 to 18.45), reflecting an improvement of HRQOL.
Using a linear least squares regression, graft loss 
(β = – 0.719; p < 0.01), incidence of depression (β
= – 0.181 p < 0.05), and NODAT (β = 0.227; p < 0.05) 
explained 22% (adjusted R2 = 0.223) of the vari-
ability of utility change scores. Hypersensitized 
patients (β = 17.175; p < 0.05), autosomal dominant 
polycystic disease (β =18.576; p < 0.05) and IS switch
(β = 17.348 p < 0.05) explained 28% (adjusted R2
= 0.284) of the variability of EQ-VAS change scores.
Responses to the EQ-5D dimensions showed that 
patients reported more problems with pain/discom-
fort and anxiety/depression on HD and KT. Pain/
discomfort improved after KT.
 Costs
The average annual cost of HD was 32,567.57€/
patient. Eighty per cent of this value was allocated to 
the comprehensive price (24,444.68€), 6% both to trans-
portation (1,863.16€) and lost productivity (1,817.36€), 
4% to medication (1,301.55€), and the remainder to 
diagnostic procedures and hospital admissions.
Costs of cadaveric and living renal donation were 
4,796.17€ and 6,051.30€, respectively. The mean cost 
of follow-up of living donor in the first year was 
823.29€, reduced by half thereafter. The eligibility costs 
averaged 2,845.25€ in the year of acceptance onto 
the transplant list and 1,184.33€ in subsequent years.
Total costs on the first, second and third years of 
KT averaged 60,210.09€, 12,956.77€ and 11,778.65€, 
respectively. Medication costs decreased in absolute 
amounts over time, accounting for 24% of the costs 
Table I
Characteristics of respondents to the questionnaires
Waitlisted 
patients
N = 384
Transplant  
recipients
N = 65
Age: median (percentiles 25-75) 51 years 
(42-59)
55 years 
(45-61)
Gender
Male 241 (62.8%) 41 (63.1%)
Educational attainment
None 18 (4.7%) 1 (1.5%)
Basic level 193 (50.3%) 34 (52.3%)
Secondary level 137 (35.7%) 26 (40%)
Higher Education 36 (9.4%) 4 (6,2%)
Monthly income 
≤ minimum wage 132 (34.4%) 28 (43.1%)
> minimum wage 252 (65.6%) 37 (56.9%)
Professional activity
Retired 204 (53.1%) 36 (55.4%)
Working 180 (46.9%) 29 (38.5%)
Aetiology of renal disease
Chronic glomerulonephritis 123 (32%) 21 (32.3%)
Nephroangiosclerosis hypertensive 82 (21.4%) 16 (24.6%)
Autosomal dominant polycystic 46 (12%) 7 (10.8%)
Diabetes Mellitus 28 (7.3%) 6 (9.2%)
Co-morbidities: median (percentiles 25-75) 1 (0-1) 2 (1-3)
Time on haemodialysis:  
median (percentiles 25-75)
49 months  
(26-96)
91 months  
(79-104)
Hospitalization last year 100 (26%) 20 (30.8%)
HLA sensitization: median (percentiles 25-75) 0 (0 – 0) 0 (0 – 8.5)
Hypersensitized patient 2 (0.5%) 7 (10.8%)
Marginal recipient 33 (50.8%)
High immunological risk 33 (50.8%)
HLA- Mismatches: median (percentiles 25-75) 4 (3-6) 
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during the first year and 50-52% thereafter. Diagnostic 
procedures and consultations represented a constant 
proportion of annual costs (8-11%).
Hypersensitized patients (87,918.43 vs. 56,865.98€; 
p < 0.01), high immunological risk (72,209.20 vs. 
47,836.01€; p < 0.001) and graft failure (84,030.92 
vs. 59,132.53€; p < 0.05) had higher costs at 1-year.
The mean primary hospitalization cost was 
18,740.74€ (median 15,348.86€), representing 31% 
of 1-year costs. Other major components of costs 
were medication (10,745.88€), other hospitalizations 
(5,494.89€), diagnostic procedures (3,792.81€) and 
consultations (3,691.70€).
Sixty-two rehospitalizations occurred during the 
first year, 16 during the second year and three during 
the third year. The main causes were infections and 
graft dysfunction. Age, DM, HLA-mismatches and 
cardiac events during the initial hospitalization were 
significant predictors of 1-year readmission (p < 0.001) 
(Table 2). Age decreases the risk of readmission by 
9% per year (p < 0.05) while female gender and 
diabetics had nine and 24 times, respectively, the 
risk of being hospitalized (p < 0.05), HLA-mismatches 
duplicates (p < 0.05) and cardiac events carried six 
times the risk of readmission (p < 0.05).
Lost productivity caused by early retirement rep-
resented 6% of annual costs on HD, amounting to 
1,817.36€/patient. After KT, morbidity costs repre-
sented 2% of annual costs in the first year.
Changes in HRQOL and costs over time and its 
significant predictors are summarized in Table III.
Table III
Costs and HRQOL in haemodialysis and after kidney transplantation
Haemodialysis Kidney transplantation
Statistical tests p
Baseline 3 months 6 months Year-1 Year-2
EQ-5D utility 0.80 0.85 a) 0.85 0.81 0.85 Friedman test < 0.01
EQ-VAS score 70 80 b) 80 b) 85 b) 85 c) Friedman test < 0.001
Utility change scores ∆ EQ-5D utility = EQ-5D Year 2 – EQ-5D Baseline Multiple linear regression < 0.01 d)
EQ-VAS change scores ∆ EQ-VAS = EQ-VAS Year 2 – EQ-VAS baseline Multiple linear regression = 0.01 e)
Costs 32,567.57€ 60,210.09€ 12,956.77€ Multiple linear regression
< 0.001 at year-1 f)
< 0.01 at year-2 g)
Cost-utility ratio
Custos Tx – Custos Hd
 = 5,451.63€
QALY Tx – QALY
a) Paired sign test: p < 0.01 compared with haemodialysis.
b) Paired sign test: p < 0.001 compared with haemodialysis.
c) Paired sign test: p < 0.01 compared with haemodialysis.
d) ‘Graft loss’ (p < 0.01) and ‘Depression’ (p < 0.05) were independent predictors of worse utility and ‘NODAT’ was associated with better HRQOL (p < 0.05)
e) ‘Autosomal dominant polycystic disease’ and ‘immunosuppressive switch’ were independent predictors of worse EQ-VAS (p < 0.05); ‘Hipersensitized patients’ were associated 
with better HRQOL (p < 0.05).
f) ‘HLA- mismatches’ was an independent predictor of higher costs at year-1 (p < 0.05).
g) ‘Age’ was an independent predictor of lower costs at year-2 (p < 0.05); ‘Pre-existing cardiac disease’ and ‘Cold ischaemic time’ were independent predictors of higher costs at 
year-2 (p < 0.05).
Table II
Risk for admissions
Variable Parameter estimate P-value Odds ratio 95% CI for odds ratio
Age -0.084 0.028 0.920 0.854 – 0.991
Gender 2.206 0.006 9.082 1.893 – 43.559
Diabetes Mellitus 3.187 0.023 24.211 1.551 – 377.93
Mismatches-HLA 0.720 0.019 2.055 1.126 – 3.749
Cardiac events 1.869 0.028 6.484 1.225 – 34.312 
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 Cost-utility of dialysis
Waiting on dialysis resulted in 0.76 utilities and 
this figure was assumed to be constant thereafter. As 
costs and utilities in the second and third years of KT 
did not differ significantly, our model considers that 
KT leads to 0.74 utilities during the first year and 0.77 
thereafter. The incremental cost utility ratio (ICER) was 
5,534.46€/QALY (Table IV). Applying three and five 
per cent discount rate to costs and QALY, ICER was 
3,764.76€/QALY and 2,004.75 €/QALY, respectively.
 Sensitivity analysis
Applying a three and five per cent discount rate 
only to costs, ICER was 2,869.78€/QALY and 
1,263.98€/QALY, respectively. When indirect costs 
were excluded, ICER was 5,436.41€/QALY. KT was 
found to be dominant over HD when assuming equal 
survival as it yielded both lower costs (259,744.35€
vs. 534,108.15€) and higher benefits (12.59 QALY vs. 
12.46 QALY). The inclusion of costs for organ pro-
curement increased ICER by 35%.
 DISCUSSION
This study shows that KT is cost-effective com-
pared to HD, confirming previous studies. To our 
knowledge, this is the first cost-utility analysis of KT 
vs. HD performed in Portugal. Our study was based 
on prospectively collected data and included the 
assessment of direct utilities and both direct and 
indirect costs, namely: costs related to selection of 
candidates for KT, living and cadaveric donation, 
transportation, hospital admissions and productivity 
changes. We were able to determine the real burden 
of KT and HD on the healthcare system and society, 
and we identified subgroups of patients with 
differing risks after KT, which may help to improve 
the effectiveness of healthcare delivery.
Our research showed differences from that yielded 
by a previous cost analysis of ESRD treatment in 
Portugal16. Our methodology considered the addi-
tional issues: inclusion of both costs and health 
outcomes from a prospective observational study; 
collection of detailed cost data and measurement of 
patients preference-adjusted health status; extrapola-
tion of costs and utilities beyond the study period 
over patient lifetime. Moreover, we calculate the ICER 
of KT vs. HD, allowing comparison across different 
health interventions in order to prioritize them.
In our study, ESRD patients rated their HRQOL 
higher compared to various international studies8,17. 
Dialysis patients in Portugal may have better acces-
sibility to healthcare, and nephrologists refer them 
to whatever specialized care they need, explaining 
the higher level of satisfaction with the provision of 
healthcare compared to the general population.
As earlier studies have demonstrated18, lower util-
ity scores on HD were significantly associated with 
female gender and lower levels of schooling.
The HRQOL remained stable on HD patients. The 
perceived health by patients during HD is directly 
related to their expectations after KT19. The positive 
change of HRQOL observed at 3 months, in transplant 
recipients, reflects the sense of freedom from HD 
and the surge in well-being of patients shortly after 
KT. No other change of utilities occurred despite the 
occurrence of a sustained increase in EQ-VAS scores.
After KT, 22% of patients were prescribed antide-
pressants, and thus apparently did not experience 
the sustained improvement of HRQOL observed in 
a previous study20. On HD, due to the limitations 
imposed by illness and time to receive care, patients 
Table IV
Incremental analysis
Utilities Costs/year Life expectancy QALY Total costs
Haemodialysis 0.76 32,567.57€ 6.7 years 5.092 218,202.72€
Transplantation 16.4 years 12.598 259,744.35€
1st year 0.74 60,210.09€ 1st year 0.74 60,210.09€
Subsequent years 0.77 12,956.77€ 15.4 years 11.858 199,534.26€ 
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and their families accept a lower income generated 
by early retirement. After a successful transplant, a 
new reality emerges: there is plenty of time, dimin-
ished financial resources, and employment is only a 
remote possibility. No retired transplant recipient 
returned to work, corroborating the maintenance of 
professional activity on HD as the main predictor of 
employment after KT21. Working solutions are 
required, namely, a review of scheduled working 
time to reverse the high societal impact of lost pro-
ductivity on ESRD. Taking equity considerations into 
account, a general wage rate was used instead of 
the actual wages of ESRD patients.
Patients with graft failure reported lower utilities. 
The lowest utility values from patients who had lost 
their graft can generate a health state, rated by the 
general population as worse than death.
The costs during the first year (60,210.09€) were 
higher compared to previous studies [6,22-24]. The 
inclusion of patients who had lost their graft, not 
stated in those studies, may explain this discrepancy. 
We found higher costs in this specific subgroup that 
averaged 36,249.51€ on initial hospitalization, 
84,030.92€ during the first year and 37,674.80€ in 
subsequent years.
High-immunological risk patients presented higher 
costs at initial hospitalization and year-1. The chosen 
IS protocol, serial monitoring of donor-antibody and 
antibody rejection treatment could explain the dif-
ference but the favourable outcomes supported the 
use of the newer IS agents.
We found that HLA-mismatches increase the costs 
of initial hospitalization by 75% and 41% during the 
first year of KT, and carried a two-fold risk of read-
mission during the first year. A previous study noticed 
the relevance of HLA matching25.
Underfinancing of hospital services and organ 
procurement organizations impacts negatively on 
transplantation26. The specific DRG rate for KT is 
9,296.58 €, not covering the expenses incurred dur-
ing the primary hospitalization. A revision of this 
price is a priority as the actual reimbursement model 
acts as a disincentive to expand KT programmes.
Using a predictive model to assess the risk of 
hospital readmissions may help to reduce future 
inpatient expenditures. In our study, the odds-ratio 
for readmission was 24 for diabetics and six for cardiac 
patients, suggesting the need of a programme targeted 
at patients with DM and cardiovascular disease. Pre-
existing cardiovascular disease proved to have a nega-
tive impact on HRQOL during the first two years of 
KT. It also adversely affected graft function in year-1, 
increased the occurrence of cardiac events on initial 
hospitalization and readmissions during the first year. 
Although not an absolute contraindication for KT, 
these findings raise questions about the best treat-
ment options for this specific subgroup.
The negative impact of ECD on morbidity (lower 
graft survival, higher costs and more rehospitaliza-
tions) was limited to the first year, supporting the 
old-for-old allocation on KT as, according to a previ-
ous study27, older people benefit from a lower wait-
ing time to KT.
The incremental analysis showed that KT costs 
41,541.63€ more than HD but resulted in 7.51 addi-
tional QALY, representing seven years and five 
months of perfect health. The incremental cost-utility 
ratio was 5,534.46€/QALY. The sensitivity analysis 
demonstrates the robustness of our conclusions. The 
assumption of equal life expectancy for HD and KT 
was the parameter with the greatest impact in our 
results.
This is a single centre study. Several factors sup-
port the generalizability of our findings to the national 
context: i) In Portugal, the provision of dialysis care 
is delivered by an organized referral network28. i) 
To meet parameters of clinical effectiveness, there 
are guidelines within the units of dialysis set down, 
enforced and currently audited by the health authori-
ties, which means that there are few variations in 
clinical practice; ii) Listing into two transplant units 
minimized potential bias in the eligibility criteria to 
KT; iii) Although recruited from a single hospital, the 
studied population had different geographic and 
socioeconomic backgrounds.
This work has several strengths: a) As a longitu-
dinal study, it allowed us to establish links between 
predictors and potential risk factors for HRQOL and 
costs; b) An intention-to-treat analysis was used, 
including patients with failed grafts and those who 
had died; c) EQ-5D utilities based on actual measure-
ment can be incorporated into future economic 
A prospective assessment of renal transplantation versus haemodialysis: 
which therapeutic modality is good value for society?
Nefro - 28-4 - MIOLO.indd   307 29/12/2014   14:18:23
308    Port J Nephrol Hypert 2014; 28(4): 300-308
CMYKP
evaluations; d) A micro-costing approach was used 
to estimate costs; e) Handling uncertainty with a 
series of one-way sensitivity analyses proved the 
robustness of the model outcomes which minimized 
the study limitations of having small sample size 
and being a single-centre analysis.
Using EQ-5D value set for United Kingdom can 
introduce a potential bias. EuroQol Group recom-
mended its use because preferences weights for 
Portuguese population were not available.
We conclude that KT is cost-effective compared 
to HD, cost saving at 2 years and 5 months, accord-
ing with previous studies that reported lower costs 
after 2 years of KT [24;29]. When assuming equal 
life expectancy for both modalities, KT is dominant 
over HD. The identification of patient subgroups 
categorized by baseline characteristics will help in 
the creation of reimbursement models adjusted to 
risk, preventing the issue of adverse selection. That 
would represent progress in efficiency and equity, 
the prime objectives of healthcare.
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